Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GAUTAM BORTHAKUR and NAVEEN PEMMARAJU.
GAUTAM BORTHAKUR
Connection Strength
11.876
NAVEEN PEMMARAJU
  1. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol. 2015; 5:29.
    View in: PubMed
    Score: 0.529
  2. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol. 2014; 4:130.
    View in: PubMed
    Score: 0.504
  3. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol. 2014 Dec; 93(6):543-4.
    View in: PubMed
    Score: 0.497
  4. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
    View in: PubMed
    Score: 0.242
  5. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
    View in: PubMed
    Score: 0.228
  6. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 Nov; 97(11):1427-1434.
    View in: PubMed
    Score: 0.224
  7. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res. 2022 08; 119:106884.
    View in: PubMed
    Score: 0.219
  8. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
    View in: PubMed
    Score: 0.219
  9. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022 05; 97(5):574-582.
    View in: PubMed
    Score: 0.215
  10. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
    View in: PubMed
    Score: 0.208
  11. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer. 2021 04 15; 127(8):1246-1259.
    View in: PubMed
    Score: 0.198
  12. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leuk Lymphoma. 2021 03; 62(3):528-537.
    View in: PubMed
    Score: 0.197
  13. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol. 2020; 10:1538.
    View in: PubMed
    Score: 0.194
  14. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. 2020 10; 191(1):e10-e13.
    View in: PubMed
    Score: 0.193
  15. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
    View in: PubMed
    Score: 0.192
  16. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 05 04; 10(5):48.
    View in: PubMed
    Score: 0.190
  17. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother. 2019 Sep; 20(13):1637-1644.
    View in: PubMed
    Score: 0.178
  18. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma. 2019 11; 60(11):2829-2831.
    View in: PubMed
    Score: 0.177
  19. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. 2018 11; 93(11):E357-E360.
    View in: PubMed
    Score: 0.169
  20. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.165
  21. Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. 2018 03; 32(2):96-105.
    View in: PubMed
    Score: 0.158
  22. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):845-850.
    View in: PubMed
    Score: 0.155
  23. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk. 2016 Apr; 16(4):213-222.e2.
    View in: PubMed
    Score: 0.141
  24. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
    View in: PubMed
    Score: 0.130
  25. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol. 2014; 4:297.
    View in: PubMed
    Score: 0.130
  26. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
    View in: PubMed
    Score: 0.129
  27. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.
    View in: PubMed
    Score: 0.123
  28. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Apr 09.
    View in: PubMed
    Score: 0.062
  29. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 Apr 04.
    View in: PubMed
    Score: 0.062
  30. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr; 11(4):e287-e298.
    View in: PubMed
    Score: 0.062
  31. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 Feb 28.
    View in: PubMed
    Score: 0.062
  32. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024 Feb 27; 8(4):927-935.
    View in: PubMed
    Score: 0.062
  33. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915.
    View in: PubMed
    Score: 0.062
  34. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024 Apr; 99(4):792-796.
    View in: PubMed
    Score: 0.062
  35. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 Mar; 38(3):545-556.
    View in: PubMed
    Score: 0.061
  36. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
    View in: PubMed
    Score: 0.061
  37. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657.
    View in: PubMed
    Score: 0.061
  38. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
    View in: PubMed
    Score: 0.060
  39. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica. 2023 09 01; 108(9):2331-2342.
    View in: PubMed
    Score: 0.060
  40. Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.
    View in: PubMed
    Score: 0.060
  41. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2023 11; 203(4):581-592.
    View in: PubMed
    Score: 0.060
  42. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
    View in: PubMed
    Score: 0.059
  43. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
    View in: PubMed
    Score: 0.059
  44. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol. 2023 05; 7:e2200707.
    View in: PubMed
    Score: 0.058
  45. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.
    View in: PubMed
    Score: 0.058
  46. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Res Sq. 2023 Feb 23.
    View in: PubMed
    Score: 0.058
  47. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer. 2023 02 15; 129(4):560-568.
    View in: PubMed
    Score: 0.057
  48. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606.
    View in: PubMed
    Score: 0.056
  49. Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv. 2022 10 11; 6(19):5546-5549.
    View in: PubMed
    Score: 0.056
  50. Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452.
    View in: PubMed
    Score: 0.056
  51. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022 Nov; 97(11):1413-1418.
    View in: PubMed
    Score: 0.056
  52. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
    View in: PubMed
    Score: 0.056
  53. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations. Acta Haematol. 2022; 145(5):529-536.
    View in: PubMed
    Score: 0.055
  54. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
    View in: PubMed
    Score: 0.055
  55. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
    View in: PubMed
    Score: 0.055
  56. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77.
    View in: PubMed
    Score: 0.055
  57. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022 May; 9(5):e350-e360.
    View in: PubMed
    Score: 0.055
  58. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
    View in: PubMed
    Score: 0.055
  59. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2022 09; 63(9):2161-2170.
    View in: PubMed
    Score: 0.054
  60. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022 07; 97(7):856-864.
    View in: PubMed
    Score: 0.054
  61. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
    View in: PubMed
    Score: 0.053
  62. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma. 2021 12; 62(14):3402-3410.
    View in: PubMed
    Score: 0.052
  63. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2021 11 15; 127(22):4213-4220.
    View in: PubMed
    Score: 0.052
  64. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
    View in: PubMed
    Score: 0.052
  65. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
    View in: PubMed
    Score: 0.052
  66. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021 08 01; 106(8):2121-2130.
    View in: PubMed
    Score: 0.052
  67. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551.
    View in: PubMed
    Score: 0.051
  68. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771.
    View in: PubMed
    Score: 0.051
  69. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
    View in: PubMed
    Score: 0.051
  70. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
    View in: PubMed
    Score: 0.051
  71. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.051
  72. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
    View in: PubMed
    Score: 0.051
  73. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.
    View in: PubMed
    Score: 0.051
  74. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.051
  75. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021 04 27; 5(8):2156-2164.
    View in: PubMed
    Score: 0.051
  76. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183.
    View in: PubMed
    Score: 0.051
  77. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
    View in: PubMed
    Score: 0.051
  78. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
    View in: PubMed
    Score: 0.051
  79. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499.
    View in: PubMed
    Score: 0.051
  80. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60.
    View in: PubMed
    Score: 0.050
  81. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021 03 01; 106(3):894-898.
    View in: PubMed
    Score: 0.050
  82. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.
    View in: PubMed
    Score: 0.050
  83. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25.
    View in: PubMed
    Score: 0.050
  84. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.
    View in: PubMed
    Score: 0.050
  85. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
    View in: PubMed
    Score: 0.050
  86. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):338-344.
    View in: PubMed
    Score: 0.050
  87. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
    View in: PubMed
    Score: 0.050
  88. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma. 2021 04; 62(4):909-917.
    View in: PubMed
    Score: 0.049
  89. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
    View in: PubMed
    Score: 0.049
  90. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
    View in: PubMed
    Score: 0.049
  91. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.
    View in: PubMed
    Score: 0.049
  92. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol. 2020; 10:588876.
    View in: PubMed
    Score: 0.049
  93. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
    View in: PubMed
    Score: 0.049
  94. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329.
    View in: PubMed
    Score: 0.049
  95. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.049
  96. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315.
    View in: PubMed
    Score: 0.049
  97. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
    View in: PubMed
    Score: 0.048
  98. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127.
    View in: PubMed
    Score: 0.048
  99. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.048
  100. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 09; 95(9):E225-E228.
    View in: PubMed
    Score: 0.048
  101. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1690-1699.
    View in: PubMed
    Score: 0.047
  102. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.
    View in: PubMed
    Score: 0.047
  103. Long-term follow-up of lower dose dasatinib (50?mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020 01 01; 126(1):67-75.
    View in: PubMed
    Score: 0.046
  104. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.
    View in: PubMed
    Score: 0.045
  105. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
    View in: PubMed
    Score: 0.045
  106. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020 01; 11(1):19-23.
    View in: PubMed
    Score: 0.044
  107. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
    View in: PubMed
    Score: 0.044
  108. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019 01 16; 9(2):7.
    View in: PubMed
    Score: 0.043
  109. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.043
  110. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1.
    View in: PubMed
    Score: 0.043
  111. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019 Jan; 6(1):e29-e37.
    View in: PubMed
    Score: 0.043
  112. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.042
  113. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
    View in: PubMed
    Score: 0.042
  114. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
    View in: PubMed
    Score: 0.042
  115. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018 07 01; 124(13):2740-2747.
    View in: PubMed
    Score: 0.041
  116. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018 Jul; 97(7):1183-1191.
    View in: PubMed
    Score: 0.041
  117. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. 2018 Apr; 5(4):e136-e146.
    View in: PubMed
    Score: 0.041
  118. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.040
  119. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90.
    View in: PubMed
    Score: 0.040
  120. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.
    View in: PubMed
    Score: 0.040
  121. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.
    View in: PubMed
    Score: 0.040
  122. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep. 2017 09 12; 7(1):11253.
    View in: PubMed
    Score: 0.040
  123. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015.
    View in: PubMed
    Score: 0.039
  124. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
    View in: PubMed
    Score: 0.039
  125. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.
    View in: PubMed
    Score: 0.039
  126. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.039
  127. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.039
  128. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017 Jul; 92(7):674-682.
    View in: PubMed
    Score: 0.039
  129. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. 2017 Jul; 92(7):599-606.
    View in: PubMed
    Score: 0.039
  130. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
    View in: PubMed
    Score: 0.038
  131. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.037
  132. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
    View in: PubMed
    Score: 0.037
  133. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23.
    View in: PubMed
    Score: 0.036
  134. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.
    View in: PubMed
    Score: 0.035
  135. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62.
    View in: PubMed
    Score: 0.035
  136. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48.
    View in: PubMed
    Score: 0.035
  137. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
    View in: PubMed
    Score: 0.034
  138. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83.
    View in: PubMed
    Score: 0.034
  139. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63.
    View in: PubMed
    Score: 0.034
  140. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6.
    View in: PubMed
    Score: 0.034
  141. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
    View in: PubMed
    Score: 0.033
  142. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
    View in: PubMed
    Score: 0.033
  143. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34.
    View in: PubMed
    Score: 0.033
  144. Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363.
    View in: PubMed
    Score: 0.033
  145. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
    View in: PubMed
    Score: 0.033
  146. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
    View in: PubMed
    Score: 0.032
  147. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
    View in: PubMed
    Score: 0.032
  148. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.
    View in: PubMed
    Score: 0.031
  149. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
    View in: PubMed
    Score: 0.030
  150. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6.
    View in: PubMed
    Score: 0.030
  151. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
    View in: PubMed
    Score: 0.030
  152. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
    View in: PubMed
    Score: 0.029
  153. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol. 2013 Jun; 161(5):659-666.
    View in: PubMed
    Score: 0.029
  154. Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):93-6.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.